(S)-glycidyl carbazol-2-yl ether | 256373-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (S)-glycidyl carbazol-2-yl ether
• 英文别名: 2-[[(2S)-oxiran-2-yl]methoxy]-9H-carbazole
• CAS: 256373-49-6
• 化学式: C₁₅H₁₃NO₂
• 分子量: 239.274
• InChiKey: WQUGMHSNHWIBJY-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-hydroxy-4-(quinolin-3-yl)piperidine 、 (S)-glycidyl carbazol-2-yl ether 生成 1-((2S)-hydroxy-3-(carbazol-2-yloxy)prop-1-yl)-4-hydroxy-4-(quinolin-3-yl)piperidine
  参考文献：
  名称：

  5-HT1F antagonists

  摘要：

  这项发明提供了化学式I中的5-HT1f拮抗剂：其中AR1、AR2、R和R'如规范中所定义。

  公开号：

  US06242450B1

文献信息

• Use of 5HT-1F receptor antagonists for treating anxiety disorders
  申请人：ELI LILLY AND COMPANY

  公开号：EP0976747A3

  公开（公告）日：2000-09-13

  The present invention provides a method for the treatment of prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.

  本发明提供了一种治疗预防焦虑症的方法，包括向需要此类治疗的哺乳动物施用一种5-HT1F受体拮抗剂。
• METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR
  申请人：Chen Gang

  公开号：US20080262226A1

  公开（公告）日：2008-10-23

  A method is provided for making compounds comprising a beta-adrenergic inhibiting moiety and a linking moiety, the method comprising: a) reacting a compound of formula (A): (R 1 —(CH—O—CH 2 )) with at least one of NH 3 , NH 4 , NH 4 ClNH 3 and R 12′ NH 2 thereby forming a compound of formula (B): (R 1 —CH(OH)—CH 2 —NHR 12′ ); and b) reacting a compound of formula (B) with a compound of formula (C): (R 3 ═O), thereby forming a compound of formula (D): (R 1 —COH—CH 2 —N(R 3 )(R 12′ )), wherein R 1 comprises the beta-adrenergic inhibiting moiety or comprises the beta-adrenergic inhibiting moiety when bonded to —COH—CH 2 —N(R 12′ )— of formula (D); R 3 comprises the linking moiety and is bonded to the =0 of formula (C) via a carbon atom; and R 12′ is selected from hydrogen and a protecting group.

  提供了一种制备含有β-肾上腺素受体抑制基团和连接基团的化合物的方法，该方法包括：a)将式（A）的化合物：（R1-（CH-O-CH2））与NH3、NH4、NH4ClNH3和R12'NH2中的至少一种反应，从而形成式（B）的化合物：（R1-CH（OH）-CH2-NHR12'）；b)将式（B）的化合物与式（C）的化合物反应：（R3═O），从而形成式（D）的化合物：（R1-COH-CH2-N（R3）（R12'）），其中R1包括β-肾上腺素受体抑制基团，或者在与式（D）的—COH-CH2-N（R12'）—结合时包括β-肾上腺素受体抑制基团；R3包括连接基团，并通过碳原子与式（C）的=0结合；R12'选择自氢和保护基团。
• US6242450B1
  申请人：——

  公开号：US6242450B1

  公开（公告）日：2001-06-05
• [EN] TREATMENT OF ANXIETY DISORDERS<br/>[FR] TRAITEMENT DES TROUBLES ANXIEUX
  申请人：LILLY CO ELI

  公开号：WO2000006082A2

  公开（公告）日：2000-02-10

  The present invention provides a method for the treatment or prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.
• [EN] 5-HT1F ANTAGONISTS<br/>[FR] ANTAGONISTES DE 5-HT1F
  申请人：LILLY CO ELI

  公开号：WO2000006166A1

  公开（公告）日：2000-02-10

  This invention provides 5-HT1F antagonists of Formula (I) where AR1, AR2, R, and R' are as defined in the specification.